NeurologyLive

11/06/2025

⏰ Treat early, feel better.

A new study of over 55,000 people shows that using the Nerivio® wearable within one hour of migraine onset can double your chances of relief compared to waiting longer.

✅ Pain relief up 18.5%
✅ Functional freedom up 14.5%
✅ Fewer migraine symptoms (light, sound, nausea)

This research—published in Cephalalgia—is the largest migraine study ever conducted, proving that timing matters when it comes to migraine care.

💡 The Nerivio device offers drug-free relief through gentle electrical stimulation controlled by your smartphone.

Learn more: https://hubs.li/Q03S5GK80

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

11/06/2025

🧠 Your smile could say more about your stroke risk than you think.

A new study published in Neurology® found that people with both gum disease and cavities had an 86% higher risk of stroke and an 88% higher risk of major heart events compared to those with good oral health.

Even gum disease alone increased risk by 44%.

Researchers say this highlights how oral health is directly connected to heart and brain health — and that routine dental care may help lower the risk of serious vascular disease.

🪥 Brushing, flossing, and regular checkups aren’t just for your teeth — they could protect your heart and brain too! ❤️🧠

Read more here: https://hubs.li/Q03R_Rp80

A 2025 study published in Neurology® found that people with both gum disease and dental cavities face significantly higher long-term risks of stroke and major cardiovascular events compared with those with good oral health.

11/06/2025

🌟 New hope for people living with ALS!

Early Phase 2 trial results for SPG302, a daily oral drug from Spinogenix, show that 82% of treated patients had stable or improved ALS progression — and that the therapy slowed disease decline by 76% compared to historical data.

The drug was well-tolerated and showed signs of synaptic regeneration, a completely new way of addressing ALS at the cellular level.

Researchers say these findings could pave the way for the first regenerative therapy in ALS. Spinogenix also plans to make the drug available to more patients through an expanded access program. 💙

Read more: https://hubs.li/Q03R_dyt0

Spinogenics presents promising data on SPG302, a daily tablet showing cognitive improvements in Alzheimer's patients with excellent safety profiles.

11/06/2025

✨ Big news for the rare disease community!

The FDA has approved Kygevvi, a combination of doxecitine and doxribtimine, as the first-ever treatment for thymidine kinase 2 deficiency (TK2d) — a rare genetic disorder that weakens muscles and affects breathing.

Clinical trials showed life-changing benefits, including an 86% reduction in risk of death and improved motor function for many patients.

This milestone offers new hope for families affected by TK2d and marks a major step forward in mitochondrial medicine.

Kygevvi, developed by UCB, is expected to be available in early 2026. 💙

Read Here: https://hubs.li/Q03RWDq80

UCB's Kygevvi becomes the first FDA-approved treatment for thymidine kinase 2 deficiency, offering hope to patients with this rare neuromuscular disorder.

11/04/2025

🩺 New Study for Myasthenia Gravis Treatment

A new Phase 3 clinical study, called RELIEVE, is exploring the safety and effectiveness of remibrutinib for people with generalized myasthenia gravis (gMG).

Remibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor developed by Novartis. It’s already approved for chronic spontaneous urticaria and is now being tested as a potential therapy for gMG — offering hope for a simpler, targeted treatment option.

📖 Read more here: https://hubs.li/Q03RymN30

A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.

11/04/2025

📣 Encouraging news for patients with generalized myasthenia gravis (gMG):

New 52-week data from the MINT trial show that inebilizumab provides durable improvement and sustained safety benefits.

Dr. Richard Nowak, MD, MS, explains what these results mean for the future of gMG treatment — and what to expect from upcoming long-term studies.

🎥 Watch the 5-minute video interview: https://hubs.li/Q03Rp4dq0

The associate professor of neurology at Yale School of Medicine discussed 52-week data from the phase 3 MINT trial of inebilizumab in patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]

11/04/2025

🌉 🧠 Thank you to the experts in medicine who came out to speak with us at ! Be on the lookout for these interviews coming to our site soon! American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM 🎥 💻 CGTLive

Featured:
- Kimberly Moran, PhD, MBA, of UCB Biopharma
- Richard Nowak, MD, MS, of Yale School of Medicine
- John Norbury, MD, of Virginia Commonwealth University
- Amit Sachdev, MD, of Michigan State University

View our ongoing coverage of the meeting here: https://hubs.li/Q03RB3Dy0

11/04/2025

🧠 New Hope for Families Facing Infantile-Onset Niemann-Pick Type C

In a new NeurologyLive® interview, Alexander Gold, MD, chief medical officer at Mandos Health, shares new data from the 2025 Child Neurology Society Meeting showing that adrabetadex—an investigational therapy—significantly improves survival and cholesterol trafficking in children with infantile-onset NPC.

Dr. Gold also discusses the challenges of developing therapies for this ultra-rare disease and the growing collaboration within the NPC community driving progress forward.

💬 “For families affected by infantile-onset NPC, time is precious. These data give hope for more time—more milestones, more moments.”

Read the full story: https://hubs.li/Q03Rkr0S0

The chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.

11/04/2025

🧠 This Week on NeurologyLive® — November 3, 2025

Stay up to date with the latest in neurology! This week, the NeurologyLive® team is covering trending topics and expert insights across dementia, epilepsy, movement disorders, multiple sclerosis, and more.

Whether you’re a clinician, researcher, or just passionate about brain health, you’ll find something new to explore.

🎯 Don’t miss:
✔️ In-depth analyses and interviews with thought leaders
✔️ Updates on the latest clinical news
✔️ The NeurologyLive Brain Games, our weekly quiz that puts your neurology knowledge to the test!

🧩 Play this week’s quiz and see how you score ➡️ https://hubs.li/Q03RksG20

🌐 Explore the full preview here: https://hubs.li/Q03Rkj3B0

11/04/2025

📢 At , researchers unveiled EPIC, the first head-to-head phase 3 trial comparing nipocalimab (Imaavy) and efgartigimod (Vyvgart) in generalized myasthenia gravis.
🧪 The study will enroll 80 FcRn-naïve adults and assess comparative efficacy, particularly late in the efgartigimod cycle.

Read more:

A groundbreaking trial compares nipocalimab and efgartigimod for treating generalized myasthenia gravis, promising new insights for patient care.

11/03/2025

Q&A: Alexander Gold, MD, chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.

Read here:

The chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.